2024
Platelet-Rich Plasma vs Extracorporeal Shock Wave Therapy in the Treatment of Plantar Fasciitis at 3-6 Months: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Daher M, Covarrubias O, Herber A, Oh I, Gianakos A. Platelet-Rich Plasma vs Extracorporeal Shock Wave Therapy in the Treatment of Plantar Fasciitis at 3-6 Months: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Foot & Ankle International 2024, 45: 796-803. PMID: 38419209, DOI: 10.1177/10711007241231959.Peer-Reviewed Original ResearchPlantar fascia thicknessExtracorporeal shock wave therapyRandomized controlled trialsPlatelet-rich plasmaPlantar fasciitisPlatelet-rich plasma groupShock wave therapyVisual analog scaleFascia thicknessControlled trialsMeta-analysisTreatment of plantar fasciitisExtracorporeal shock wave therapy groupPain scoresWave therapyVisual analog scale painMeta-analysis of randomized controlled trialsEffect of platelet-rich plasmaVAS pain scoresHigher pain reductionManagement of PFFoot disordersSystematic reviewInclusion criteriaPain reduction
2015
Effects of gastrocnemius recession on ankle motion, strength, and functional outcomes: a systematic review and national healthcare database analysis
Gianakos A, Yasui Y, Murawski C, Kennedy J. Effects of gastrocnemius recession on ankle motion, strength, and functional outcomes: a systematic review and national healthcare database analysis. Knee Surgery, Sports Traumatology, Arthroscopy 2015, 24: 1355-1364. PMID: 26685692, DOI: 10.1007/s00167-015-3939-3.Peer-Reviewed Original ResearchConceptsGastrocnemius recessionDorsiflexion rangeFunctional outcomeInclusion criteriaSystematic reviewMean complication rateAnkle dorsiflexion rangeFull-text reviewHealthcare database analysesPeer-reviewed journalsComplication ratePearlDiver databaseEvidence 4Neurologic conditionsEmbase databasesClinical studiesSubtalar jointAnkle motionCadaveric studyGait kinematicsNormal levelsAvailable evidencePatient informationDatabase analysisEvidence scoreBisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday
Villa J, Gianakos A, Lane J. Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. HSS Journal ® 2015, 12: 66-73. PMID: 26855630, PMCID: PMC4733702, DOI: 10.1007/s11420-015-9469-1.Peer-Reviewed Original ResearchRecent fragility fractureDrug holidayBisphosphonate treatmentFragility fracturesBone deficiencyQuestions/PurposesThe purposeHigh fracture riskBone turnover rateRisk of fractureBone mass measurementsBisphosphonate therapyDrug discontinuationPeer-reviewed journalsCase seriesDrug therapyFracture riskPurposesThe purposeClinical trialsInclusion criteriaCase controlExclusion criteriaMethodsA reviewHuman studiesPatientsElectronic databases